CN113527386A

CN113527386A - Intermediate of vaccine adjuvant MPLA, synthesis and application

Info

Publication number: CN113527386A
Application number: CN202010306826.6A
Authority: CN
Inventors: 高祺; 隋强; 李�根; 郑致伟; 韩子怡; 薛俊娣
Original assignee: Shanghai Institute of Pharmaceutical Industry; China State Institute of Pharmaceutical Industry
Current assignee: Shanghai Institute of Pharmaceutical Industry; China State Institute of Pharmaceutical Industry
Priority date: 2020-04-17
Filing date: 2020-04-17
Publication date: 2021-10-22
Anticipated expiration: 2040-04-17
Also published as: CN113527386B

Abstract

The invention discloses an intermediate of vaccine adjuvant MPLA, synthesis and application. The intermediate provided by the invention takes allyl phosphate ligand as a source of phosphate group in MPLA, takes Nap as a protecting group, and can be conveniently removed in subsequent operations; the synthetic intermediate has short route and obviously increased total yield. Provides a basis for the synthesis and amplification of MPLA.

Description

Intermediate of vaccine adjuvant MPLA, synthesis and application

Technical Field

The invention relates to an intermediate of vaccine adjuvant MPLA, synthesis and application.

Background

MPLA is the innermost liposome (Lipid a) derived from endotoxin (LPS) in the cell wall of gram-negative bacteria, Monophosphoryl Lipid a (hereinafter abbreviated as MPL). Lipid A is an amphiphilic structure, is also a key structure of gram-negative bacteria with toxicity and immunogenicity, and can cause immune response of organisms. It can therefore be added to vaccines as an adjuvant to increase the immunogenicity of the vaccine; generally, although the attenuated live vaccine has strong immunogenicity, the attenuated live vaccine has high toxicity and may have pathogenic risks; and the non-toxic inactivated vaccine has weaker immunogenicity. The addition of the adjuvant can enhance the immunogenicity of the inactivated vaccine and does not bring pathogenic risk to the weak. Meanwhile, the use amount of the antigen is reduced, and the supply amount of the vaccine is increased. MPL is the first FDA-approved human novel immunoadjuvant substance other than aluminum salts. MPL acts on toll-like receptor 4(TLR4), and has the advantages of strong immunogenicity, clear mechanism and low toxicity. However, the existing aluminum salt adjuvant has an undefined mechanism, generates red swelling at an injection site, has a higher pain probability than MPL, and cannot generate specific cellular immunity. A plurality of new vaccine varieties adopting the MPL adjuvant system are sold in the market at home and abroad, such as hepatitis B vaccine Fendrix, cervical cancer vaccine Cerivix, herpes zoster vaccine Shingrix and malaria vaccine Mosquirix. And more than twenty are in clinical stage.

Since MPL derived from different bacteria or different serotypes of the same bacteria have different structures, the basic differences are the number/connection position of fatty chains and the carbon chain length of the fatty chains, for example, the synthesized structure of the patent is shown as follows;

n1 and n3 are independently 10, 12 or 14, and n2 and n4 are independently 8, 10 or 12.

The existing MPL source depends on biological fermentation extraction, the cost is high, the problem of heterogeneity of lipopolysaccharide is difficult to solve in the extraction process, the purity problem is easily caused, and the potential safety hazard is brought. Based on special physicochemical properties and complex structures, chemical methods are very difficult to synthesize MPL, and biological fermentation is difficult to replace. The total synthesis of MPL and its Lipid A analogues has been reported to be limited to milligram levels, and the ligands that normally provide phosphate groups are typically benzyl pyrophosphate (N, N-diazopyro) phosphine) or O-xylylene N, N-diethylphosphoramidite (N, N-diethyl-1,5-dihydro-3H-2,4, 3-benzodioxaphospho-3-amine) as the source of phosphate groups, with Bn being a permanent protecting group. These protecting groups must eventually be removed using hydrogenation conditions. For example, when the prior literature is used for preparing similar lipid A and derivatives thereof, the benzyl is used, Pd/C is required to react for 10-20 h under the atmospheric pressure or hydrogen pressurization condition, the impurities are more, and the yield is 45-68%. And the purification mode is complicated, and the method needs to use regenerated cellulose for filtration and remove the catalyst by ultrasound; then DEAE-cellulose ion exchange resin is used for separation, and a plurality of mixed solvents with different components are used as mobile phases to flush out the product. And repeatedly separating and concentrating to obtain the final product. (see Ref 1: Alla Zamyyana, Harald Sekljic, Helmut Brade. Synthesis and purity assessment of tetra-and pentaacyl Lipid A of Chlamydiacontaining (R) -3-hydroxyicosanoic acid. Tetrahedron 60(2004) 12113-12137. Ref 2: Kaustabh K.Maiti, Michael Decasto, Abu-Baker M.Abdel-Aal El-Sayed.chemical Synthesis and ProInflammatory reactions of Monophoroyl Lipid A Adjuvantation Candidata. Eur.J.Org.Chem.2010, 80-91).

The synthesis routes reported by the total synthesis of the MPL analogue at present are all longer; except that the benzyl protecting group used is difficult to remove completely at later deprotection; in order to avoid side reactions in the reaction, some temporary protecting groups are usually needed, so that a plurality of protecting groups are involved, and repeated protection and deprotection are needed; in the reported literature, the linking sequence of four fatty chains is different, or four fatty chains (0+4) or 3+1 are linked after glycosylation, so that the fatty chain connection selectivity is not strong, or the steric hindrance is large, and the selectivity is low during glycosylation. ([1] J.AM.CHEM.SOC.2007,129, 5200-5216; [2] WO 2013072768; [3] The chemical record, Vol 6,333-343(2006))

Therefore, in the current literature reports, the hydrogenation result is not ideal, the yield is low, impurities are more, the reaction time is long (generally more than 20 hours), the purification conditions are complicated, and the large-scale production is difficult to meet the commercial requirements.

Therefore, a new preparation method with short route and high total yield is urgently needed so as to synthesize MPLA in large quantity.

Disclosure of Invention

The invention aims to overcome the defect of lack of the preparation method of the traditional vaccine adjuvant MPLA, and provides an intermediate, synthesis and application of the vaccine adjuvant MPLA. The intermediate synthesized by the invention has short route and obviously increased total yield. The key intermediate of MPLA is adopted, and MPLA can be obtained after deprotection, thus providing a foundation for the synthesis and amplification of MPLA.

The present invention solves the above-mentioned problems by the following technical means.

The invention provides a preparation method of a compound shown as a formula 6, which comprises the following steps;

reacting a compound represented by the formula 5 with a solvent in the presence of a base

(2,2, 2-trifluoro-N-phenylacetylimine chloride) is subjected to imidization reaction shown in the specification to obtain the compound shown in the formula 6; wherein n1 is 10, 12 or 14, n2 is 8, 10 or 12;

in the present invention, in the general formula

Is conventional in the art and denotes the alpha configuration, beta configuration, or a mixture of alpha and beta configurations.

The operation and reaction conditions of the imidization reaction can be those conventional in the art for such imidization reactions; in the present invention, the following are preferred:

the organic solvent can be halogenated alkane solvent, and the halogenated alkane solvent can be dichloromethane and/or trichloromethane.

The amount of the organic solvent to be used is not particularly limited so as not to affect the reaction; for example, the mass-to-volume ratio of the compound represented by formula 5 to the organic solvent may be 10g/L to 100g/L (e.g., 50g/L to 80g/L, and further, e.g., 65 g/L).

The base may be an organic and/or inorganic base as is conventional in such reactions in the art, for example 1, 8-diazabicyclo [5.4.0 ]]Undec-7-ene (DBU), K₂CO₃DIPEA, NaH and Cs₂CO₃One or more of; for example DBU.

The molar ratio of the base to the compound of formula 5 can be 1:1 to 3:1 (e.g., 1.8:1 to 2.2:1, e.g., 2: 1).

The molar ratio to the compound of formula 5 can be 1:1 to 10:1 (e.g., 5:1 to 8:1, such as 6: 1).

The imidization reaction temperature may be from 0 ℃ to 50 ℃ (e.g., from 10 ℃ to 30 ℃).

The imidization reaction can be carried out under the protection of inert gas, and the inert gas can be nitrogen or argon.

The progress of the imidization reaction can be monitored by means conventional in the art (e.g., TLC, HPLC or LCMS), and is generally at the end of the reaction when the compound represented by formula 5 disappears or the content thereof is no longer reduced; the imidization time is preferably 0.2 to 5 hours (e.g., 0.3 to 1 hour).

The post-treatment of the imidization reaction may be a post-treatment conventional in the art, and for example, includes the following steps: and after the imidization reaction is finished, concentrating, separating and purifying to obtain the product. The separation and purification is preferably column chromatography, and the eluent for the column chromatography can be a mixed solution of alkalized petroleum ether and ethyl acetate (such as petroleum ether/ethyl acetate ═15:1, volume ratio, containing 0.1% by volume Et₃N)。

In a certain aspect, n1 is 10, 12, or 14 (e.g., 10 or 12), and n2 is 10.

The preparation method of the compound shown as the formula 6 can also comprise the following steps; in an organic solvent, in the presence of a TBS removing protective agent, carrying out TBS removing protective group reaction on a compound shown as a formula 4 to obtain a compound shown as a formula 5; n1 and n2 are both as defined above;

the operation and reaction conditions of the TBS protecting group removing reaction can be the conventional operation and reaction conditions in the TBS protecting group removing reaction in the field; in the present invention, the following are preferred:

in the TBS protecting group removing reaction, the organic solvent may be a cyclic ether solvent, and the cyclic ether solvent may be Tetrahydrofuran (THF).

The amount of the organic solvent to be used is not particularly limited so as not to affect the reaction; for example, the mass-to-volume ratio of the compound represented by formula 4 to the organic solvent may be 5g/L to 100g/L (e.g., 10g/L to 50g/L, and for example, 33 g/L).

The TBS removing protective agent can be a hydrofluoric acid pyridine complex (HF/pyridine, also called Olah reagent, wherein the mass percentage concentration of HF is 65-70%); preferably a pyridine solution of pyridine hydrofluoric acid complex (e.g., a 3-6.5 fold pyridine diluted solution of pyridine hydrofluoric acid complex).

The volume-to-mass ratio of the TBS removal protective agent to the compound shown in the formula 4 can be 1mL/g-20mL/g (for example, 3mL/g-10 mL/g).

The temperature of the TBS deprotection reaction may be from-80 ℃ to 50 ℃ (e.g., -40 ℃ to 30 ℃).

In one embodiment, the TBS deprotection reaction may employ the following steps: and adding the TBS removing protective agent into the mixed system of the compound shown in the formula 4 and the solvent to carry out the TBS removing protective group reaction. The addition temperature may be from-70 ℃ to-30 ℃ (e.g., -40 ℃). After the addition is finished, the temperature of the TBS deprotection reaction can be 0-30 ℃.

The progress of the TBS deprotection reaction can be monitored by means conventional in the art (e.g., TLC, HPLC or LCMS), and is generally determined as the end point of the reaction when the compound represented by formula 4 disappears or the content thereof is not reduced; the TBS deprotection reaction time is preferably 1 to 24 hours (e.g., 2 to 12 hours).

The post-treatment of the TBS deprotection reaction may be a post-treatment conventional in the art, for example, comprising the steps of: and after the TBS protecting group removing reaction is finished, quenching, extracting by using an organic solvent, drying, filtering, concentrating, separating and purifying to obtain the TBS. The quenching may be with a saturated sodium bicarbonate solution. The extracted organic solvent may be a haloalkane solvent (e.g., CH)₂Cl₂). The separation and purification is preferably column chromatography, and the eluent for the column chromatography can be petroleum ether and ethyl acetate (for example, petroleum ether: ethyl acetate: 4:1 by volume).

The preparation method of the compound shown in the formula 6 can also comprise the following steps:

step (1), carrying out phosphorylation reaction on a compound shown as a formula 3 and an allyl ligand in an organic solvent in the presence of tetrazole to obtain a mixture 1; the allyl ligand is hexadiene-N, N-diisopropyl phosphoramidite (b)

CAS number 126429-21-8);

step (2), carrying out oxidation reaction on the mixture 1 and an oxidant to obtain the compound shown as the formula 3; n1 and n2 are both as defined above;

the operation and reaction conditions of the phosphorylation reaction and the oxidation reaction may be those conventional in the art for such phosphorylation reactions and oxidation reactions; in the present invention, the following are preferred:

in step (1), the organic solvent may be a nitrile solvent (e.g., acetonitrile).

The amount of the organic solvent to be used is not particularly limited so as not to affect the reaction; for example, the mass-to-volume ratio of the compound represented by formula 3 to the organic solvent may be 5g/L to 200g/L (e.g., 40g/L to 60g/L, and further, e.g., 50 g/L).

In the step (1), the molar ratio of the tetrazole to the compound shown in the formula 3 can be 1:1-10:1 (for example, 3:1-5: 1).

In step (1), the molar ratio of the allyl ligand to the compound represented by formula 3 may be 1:1 to 5:1 (e.g., 1:1 to 3:1, and further, e.g., 1.5:1 to 2: 1).

In step (1), the temperature of the phosphorylation reaction may be-10 ℃ to 50 ℃ (e.g., 10 ℃ to 30 ℃).

In step (1), the progress of the phosphorylation reaction can be monitored by means conventional in the art (e.g., TLC, HPLC or LCMS), and is generally determined as the end point of the reaction when the compound represented by formula 3 disappears or the content thereof is not reduced; the time of the phosphorylation reaction is preferably 0.1 to 4 hours (e.g., 0.5 to 2 hours).

In the step (2), the oxidizing agent may be m-chloroperoxybenzoic acid (mCPBA). Preferably, the oxidizing agent may be in the form of a solution of the haloalkane solvent (for example, the mass-to-volume ratio of the oxidizing agent to the haloalkane solvent may be 0.01g/L to 0.05 g/L). The haloalkane solvent can be dichloromethane.

In the step (2), the molar ratio of the oxidant to the compound represented by formula 3 may be 1:1 to 5:1 (e.g., 2:1 to 3:1, and further, e.g., 2.5:1 to 3: 1).

In step (2), the temperature of the oxidation reaction may be from-80 ℃ to 10 ℃ (e.g., -40 ℃ to-10 ℃).

In step (2), the progress of the oxidation reaction can be monitored by means conventional in the art (e.g., TLC, HPLC or LCMS), and the oxidation reaction time is preferably 0.1 to 4 hours (e.g., 0.5 to 2 hours).

In step (2), the post-treatment of the oxidation reaction may be a post-treatment conventional in the art, and for example, includes the following steps: and after the oxidation reaction is finished, quenching, washing, drying, filtering, concentrating, separating and purifying to obtain the catalyst. The quenching can be performed with saturated aqueous sodium thiosulfate solution. The washing may be with a saturated sodium bicarbonate solution. The separation and purification is preferably performed by column chromatography, and the filler for column chromatography separation can be silica gel. The eluent for column chromatography separation can be petroleum ether and ethyl acetate (the volume ratio of the petroleum ether to the ethyl acetate is 8: 1).

The preparation method of the compound shown in the formula 6 can also comprise the following steps: in organic solvents, in Borane (BH)₃) Lewis acid and H₂In the presence of O, carrying out a selective reduction ring-opening reaction on the compound shown as the formula 2 as shown in the specification to obtain the compound shown as the formula 3; n1 and n2 are both as defined above;

the operation and reaction conditions of the selective reduction ring-opening reaction can be the conventional operation and reaction conditions in the selective reduction ring-opening reaction in the field; in the present invention, the following are preferred:

in the selective reduction ring-opening reaction, the organic solvent may be a cyclic ether solvent, and the cyclic ether solvent may be Tetrahydrofuran (THF). The amount of the organic solvent to be used is not particularly limited so as not to affect the reaction; for example, the mass-to-volume ratio of the compound represented by formula 2 to the organic solvent may be 10g/L to 200g/L (e.g., 50g/L to 150g/L, and further, e.g., 100 g/L).

The borane may be in the form of a complex, e.g. BH₃·Me₃N and/or BH₃·THF。

The molar ratio of the borane to the compound of formula 2 may be 1:1 to 5:1 (e.g. 3.5:1 to 4.5:1, for example 3.9: 1).

The Lewis acid can be AlCl₃。

The molar ratio of the borane to the Lewis acid may be from 1:1 to 1:3 (e.g., from 1:1 to 1:2, such as 1: 1.5).

Said H₂The molar ratio of O to the compound of formula 2 can be 1:1 to 5:1 (e.g., 1.5:1 to 2.5:1, e.g., 1.9: 1).

The temperature of the selective reductive ring opening reaction may be from-10 ℃ to 50 ℃ (e.g., 10 ℃ to 30 ℃).

The progress of the selective reductive ring opening reaction can be monitored by means conventional in the art (e.g., TLC, HPLC or LCMS), and is generally the end point of the reaction when the compound represented by formula 2 disappears or the content thereof is not reduced; the time for the selective reductive ring opening reaction is preferably 0.1 to 4 hours (e.g., 0.5 to 2 hours).

The post-treatment of the selective reductive ring-opening reaction may be a post-treatment conventional in the art, for example, comprising the steps of: and after the selective reduction ring-opening reaction is finished, quenching, extracting, drying, filtering, concentrating, separating and purifying to obtain the product. The quenching can be performed by adding water and a hydrochloric acid solution (e.g., 1M HCl). The solvent for the extraction may be a haloalkane solvent (e.g., dichloromethane). The washing may be with a saturated sodium bicarbonate solution. The separation and purification is preferably performed by column chromatography, and the filler for column chromatography separation can be silica gel. The eluent for column chromatography separation can be petroleum ether and ethyl acetate (the volume ratio of the petroleum ether to the ethyl acetate is 10: 1).

The preparation method of the compound shown in the formula 6 can also comprise the following steps: in an organic solvent, in the presence of a condensing agent and a catalyst, carrying out an esterification reaction shown in the specification on a compound shown in a formula 1 and a compound shown in a formula 19B to obtain a compound shown in a formula 2; n1 and n2 are both as defined above;

the operation and reaction conditions of the esterification reaction can be the operation and reaction conditions which are conventional in the esterification reaction of the type in the field; in the present invention, the following are preferred:

in the esterification reaction, the organic solvent can be a halogenated alkane solvent, and the halogenated alkane solvent can be dichloromethane and/or trichloromethane. The amount of the organic solvent to be used is not particularly limited so as not to affect the reaction; for example, the mass-to-volume ratio of the compound represented by formula 1 to the organic solvent may be 5g/L to 200g/L (e.g., 60g/L to 150g/L, and further, e.g., 100 g/L).

The catalyst may be a catalyst conventional in such reactions in the art, for example an organic base, preferably one or more of 4-Dimethylaminopyridine (DMAP), triethylamine and pyridine, preferably DMAP.

The condensing agent may be one or more of 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC. HCl), Dicyclohexylcarbodiimide (DCC) and N, N' -Diisopropylcarbodiimide (DIC), for example 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride.

The molar ratio of the condensing agent to the compound of formula 1 may be 1:1 to 5:1 (e.g., 1:1 to 3:1, and further e.g., 1.2:1 to 2: 1).

The molar ratio of the catalyst to the condensing agent can be from 0.01:1 to 1:1 (e.g., from 0.01:1 to 0.5:1, such as 0.05: 1).

The molar ratio of the compound represented by the formula 19B to the compound represented by the formula 1 may be 1:1 to 3:1 (e.g., 1:1 to 2.5:1, for example, 1.2: 1).

The esterification reaction temperature can be from-10 ℃ to 50 ℃ (e.g., 10 ℃ to 30 ℃).

The progress of the esterification reaction can be monitored by means conventional in the art (e.g., TLC, HPLC or LCMS), and is generally the end point of the reaction when the compound of formula 1 is absent or no further reduced; the esterification reaction time is preferably from 1 to 24h (e.g., from 2h to 12 h).

The workup of the esterification reaction can be a workup customary in the art, for example comprising the following steps: and after the esterification reaction is finished, washing, drying, filtering, concentrating, separating and purifying to obtain the catalyst. The washing can be carried out sequentially with a haloalkane solvent (e.g., dichloromethane), saturated sodium bicarbonate solution. The separation and purification is preferably performed by column chromatography, the filler for column chromatography separation can be silica gel, and the eluent for column chromatography separation can be petroleum ether and ethyl acetate (the volume ratio of the petroleum ether to the ethyl acetate is 10: 1).

The invention also provides a compound shown as a formula 6 and a formula 5;

wherein n1 and n2 are as defined above.

In one embodiment, the compound represented by formula 6 is any one of the following compounds:

in one embodiment, the compound represented by formula 5 is any one of the following compounds:

the invention provides a preparation method of the compound shown in the formula 5, which comprises the following steps: in an organic solvent, in the presence of a TBS removing protective agent, carrying out TBS removing protective group reaction on a compound shown as a formula 4 to obtain a compound shown as a formula 5; n1 and n2 are both as defined above;

the reaction conditions and operations in the preparation method of the compound shown in the formula 5 are as described above.

In the present invention, room temperature means 10 to 30 ℃ unless otherwise specified; "h" means hours; "overnight reaction" means reaction for 8-16 hours.

The above preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention without departing from the common general knowledge in the art.

The reagents and starting materials used in the present invention are commercially available.

The positive progress effects of the invention are as follows: the allyl phosphate ligand is used as a source of a phosphate group in MPLA, and Nap is used as a protective group, so that the allyl phosphate ligand can be conveniently removed in subsequent operations; the synthetic intermediate has short route and obviously increased total yield. Provides a basis for the synthesis and amplification of MPLA.

Detailed Description

The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.

Compound 18-a series of examples

Preparation of starting Compound 1

After a reaction flask added with 2-deoxy-1-oxo- (1, 1-dimethylethyl) dimethylsilyl-2- [ (2,2, 2-trichloroethoxy) carbonyl ] amino-3, 4, 6-triacetyl-beta-D-glucose (10g, 16.8mmol) is slowly added with a guanidinidine hydrochloride buffer solution (100mL, pH 8), stirred at room temperature for 3.5h, TLC detection raw material is consumed, the reaction solution is neutralized with a cationic resin, filtered and concentrated, the product is extracted with dichloromethane and a saturated sodium bicarbonate solution, the organic layer is collected and concentrated to obtain 2-deoxy-1-oxo- (1, 1-dimethylethyl) dimethylsilyl-2- [ (2,2, 2-trichloroethoxy) carbonyl ] amino-beta-D-glucose (1-1,8.23 g).

In a reaction flask, 1-1 and 2- (dimethoxymethyl) -naphthalene (5.1g, 25mmol, 1.5eq) were dissolved in 50mL acetonitrile, camphorsulfonic acid (0.39g, 1.69mmol, 0.1eq) was added, the reaction was stirred at room temperature for 4h, triethylamine was added to neutrality, the reaction solution was extracted with dichloromethane and saturated sodium bicarbonate solution, and the solution was separated. The organic phase was dried and dried to give a yellow solid. The crude product was passed through a silica gel frit funnel (PE: EA ═ 5:1) to afford product 1 (pale yellow solid, 6.97g) in 68.3% yield over two steps.

Compound 1:¹H NMR(400MHz,CDCl₃)δ7.96–7.50(m,7H),5.72(s,1H),5.17(d,J＝6.3Hz,1H), 4.88(d,J＝7.7Hz,1H),4.73(q,J＝12.0Hz,2H),4.36(dd,J＝10.5,5.0Hz,1H),4.13–4.01(m,1H),3.86 (t,J＝10.3Hz,1H),3.70–3.58(m,1H),3.52(td,J＝9.7,5.0Hz,1H),3.47–3.35(m,1H),2.96(s,1H),0.94 (d,J＝8.2Hz,9H),0.20–0.08(m,6H).

¹³C NMR(101MHz,CDCl₃)δ154.54,134.52,133.78,132.87,128.41,128.29,127.75,126.69,126.41, 126.07,123.93,101.97,96.33,95.30,81.52,74.85,70.71,68.68,66.20,60.73,26.94,25.59,17.90,-4.14,- 5.26.

preparation of starting Compound 23

Compound 23 was prepared by reference to the following reference and ee was determined using the same method: belma Hasdemir, Hu lya

Onar,

Asymmetry synthesis of long chain β -hydroxy fatty acid esters as new elastase inhibitors tetrahedron: Asymmetry (23)2012, 1100-1105. The document title is not normative, has been modified

Step (1) preparation of Compound 22

Meldrum's acid (64.8g, 0.45mol) and pyridine (48mL) were dissolved in CH₂Cl₂(100mL) at 0 deg.CLauroyl chloride (21, 65.6g, 0.3 mol). Stir at room temperature for 2.5 hours. After complete consumption of starting material, wash with 1M HCl (100mL) and water (100 mL). The organic layer was dried, filtered and concentrated. It was dissolved in methanol (250mL) and refluxed overnight. After the intermediate is consumed, the intermediate is concentrated and passes through Al₂O₃Purification by column chromatography (toluene: ethyl acetate 2:1) gave 22 as a pale yellow solid (59.3g, 77%).

¹H NMR(400MHz,CDCl₃)δ3.70(3H,d,J＝1.5),3.42(2H,s),2.50(2H,t,J＝7.4),1.28(18H,s), 0.90(3H,t,J＝6.6).

¹³C NMR(101MHz,CDCl₃)δ202.51,167.58,137.67,128.96,128.15,125.25,52.02,48.84,42.90, 31.92,29.62,29.47,29.38,29.35,29.01,23.43,22.68,21.31,14.04.

Step (2) preparation of Compound 23

Preparation of ruthenium catalyst: 180mg of (R) -Ru (OAc)₂(BINAP) (diacetate [ (R) - (+) -2,2 '-bis (diphenylphosphino) -1,1' -binaphthyl group)]Ruthenium (II), cas number: 325146-81-4) in CH₂Cl₂(5mL), 1.42N HCl (0.35mL) was added, and the mixture was stirred at room temperature for 1 hour and then spin-dried.

Compound 22(15g) was dissolved in methanol (50mL) with the prepared ruthenium catalyst. H₂Stirring for 6h at 65 ℃ under the condition of 1.5 MPa. After the starting material was completely completed, the reaction solution was concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate 5:1) to obtain compound 23 (white solid, 15g, 98%, ee value 98.7%).

¹H NMR(400MHz,CDCl₃)δ4.01(1H,dq,J＝11.8,4.0),3.71(3H,s),2.90(1H,d,J＝4.0),2.46(2 H,ddd,J＝25.4,16.4,6.1),1.26(18H,s),0.88(3H,t,J＝6.8).

¹³C NMR(101MHz,CDCl₃)δ173.41,67.99,51.63,41.18,36.57,31.89,29.60,29.56,29.51,29.32, 25.47,22.65,14.05.

Reaction condition screening for the preparation of compound 23:

relationship of substrate to catalyst ratio (S/C) to ee value: the reaction is completed in about 4-6h at 50 ℃ with the amount of S/C-300 catalyst, and the yield reaches over 95%. To reduce the use of catalyst, a reaction of 180mg of catalyst per 20g of substrate was attempted (S/C >300) with a yield of only 71%.

Compound 22(20g) was dissolved in methanol (50mL) with 180mg of the prepared ruthenium catalyst. H₂Stirring for 6h at 65 ℃ under the condition of 1.5 MPa. After the starting material was completely removed, the reaction mixture was concentrated and purified by silica gel column chromatography (5: 1 petroleum ether/ethyl acetate) to obtain compound 3 (white solid, 10.7g, 71%, ee 92.3%).

Analysis of the ee values of the products under the different conditions showed that the catalyst was small and the yield decreased and the ee value was only 92%. The ee value of several batches of S/C300 products is above 98%.

EXAMPLE 1 preparation of Compound 24

Compound 23(10g, 39mmol,1eq) and 2-naphthaldehyde (18.14g, 116mmol,3eq) were dissolved in THF (100mL) and TMSOTf (6.88g, 31mmol,0.8eq), (TMS) was added under ice bath₂O (37.68g, 232mmol,6eq) and Et₃SiH (15.7 g, 135mmol,3.5 eq). Reacting at 0 deg.C for 1.5 hr, and reacting with CH₂Cl₂Diluted (150mL) and saturated NaHCO₃And (6) washing. The organic layer was spin dried and recrystallized (to give methylnaphthalene as a white solid at room temperature) (petroleum ether: ethyl acetate 5:1) and filtered to remove impurities (methylnaphthalene). The filtrate (containing compound 24) was collected and spin-dried to give crude 24 as a pale yellow oily liquid, which was used in the next step without purification.¹H NMR(400MHz,CDCl₃)0.89(3H,t，J6.7),1.27–1.64(18H,m),2.35(2H,dd,J 8.4)2.49 (1H,dd,J15.0,5.3),2.62(1H,dd,J15.0,7.3),3.68(3H,s),3.88(1H,m),4.54(2H,m),7.25–7.35(7H,m).

EXAMPLE 2 preparation of Compound 20

Compound 24 prepared in example 1 was dissolved in THF-H₂O solution (5: 1, 100mL), aqueous lithium hydroxide (9.41g, 224mmol, 94mL) was added and refluxed for 12 h. After disappearance of the starting material, it was cooled to room temperature and quenched by addition of 1.5M aqueous HCl to pH 7. Subjecting the mixture to CH₂Cl₂(150mL) diluted with saturated NaHCO₃And (6) washing. The organic phase was dried and spin dried. Purification by silica gel column chromatography (5: 1 petroleum ether/ethyl acetate) gave compound 20(11.6g, 77.9% yield in two steps, colorless syrup).

¹H NMR(400MHz,CDCl₃)δ10.00(1H,s,OH),7.85(4H,dd,J＝14.5,10.8),7.53(3H,d,J＝4.2), 4.85–4.71(2H,m,NapCH₂O),4.08–3.94(1H,m,H-3),2.76(1H,dd,J＝15.2,6.9,H-2),2.64(1H,dd,J ＝15.2,4.3,H-2),1.84–1.58(2H,m,H-4),1.57–1.31(18H,m),1.00(3H,t,J＝6.0).

¹³C NMR(101MHz,CDCl₃)δ177.86,135.86,133.38,133.10,128.20,128.00,127.76,126.57,126.10, 125.99,125.89,75.94,71.71,39.81,34.37,32.05,29.77,29.71,29.48,25.27,22.82,14.26.

EXAMPLE 3 preparation of Compound 2

Dissolve compound 19-A (5g,11.7mmol) and EDC & HCl (2.25g,11.7mmol, 1.2eq) in CH₂Cl₂(50mL), stirred at room temperature for 15min, then added with Compound 1(5.93g,9.8mmol) and DMAP (0.06g,0.5mmol, 0.05eq), stirred at room temperature for 10h, and reacted with CH in turn₂Cl₂(100mL) and saturated NaHCO₃(60mL) washing. The fractions were dried, concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate 10:1) to give compound 2-a (8.6g, 86.7%, colorless syrup). TOF-MS M/z 1036.46[ M + Na ]]⁺。

δ_H(400MHz,CDCl₃)7.91(1H,s),7.82(3H,dt,J 9.3,4.9),7.54(1H,d,J 8.5),7.50–7.44(2H,m), 5.65(1H,s,NapCH),5.40–5.29(2H,m,H-3,NH),5.17(1H,dd,J 12.2,6.2,lipid-H-3),4.88(1H,d,J 7.8, H-1),4.69(2H,dd,J 48.4,12.0,Troc),4.34(1H,dd,J 10.5,4.9,H-6),3.84(1H,t,J 10.3,H-6),3.75(1H,t, J 9.4,H-4),3.62(1H,dd,J 16.8,7.7,H-2),3.54(1H,td,J 9.7,5.0,H-5),2.57(2H,ddd,J 20.5,15.2,6.3), 2.12(2H,t,J 7.4),1.56–1.41(4H,m),1.32–1.13(34H,m),0.92–0.85(15H,m),0.11(6H,d,J 8.6).

δ_C(101MHz,CDCl₃)173.41,170.19,154.12,134.29,133.71,132.85,128.38,128.11,127.67,126.47, 126.16,125.81,123.73,101.76,96.82(C-1),95.31,78.95(C-4),74.66,71.14(C-3),69.98,68.72(C-6), 66.47(C-5),59.11(C-2),39.26,34.31,33.83,31.93,29.63,29.50,29.35,29.29,29.06,25.53,25.07,24.93, 22.69,17.88,14.13,-4.21,-5.29.

EXAMPLE 4 preparation of Compound 3-a

Compound 2-a (2g,1.97mmol) was dissolved in THF (20mL) and BH was added sequentially under ice bath conditions₃·Me₃N(0.57g,7.69 mmol，3.9eq)，AlCl₃(1.52g,11.4mmol)，H₂O (69mg,3.83mmol, 1.9eq) the reaction was stirred at room temperature for 1.5 h. Water (20mL) and 1M HCl solution (20mL) were added to quench, and the reaction solution was quenched with CH₂Cl₂The resulting extract was separated (30mL), dried, concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate 10:1) to give compound 3-a (1.72g, 86%, colorless oily liquid). TOF-MS M/z 1038.52[ M + Na ]]⁺.

δ_H(400MHz,CDCl₃)7.85–7.75(4H,m),7.46(3H,dd,J 7.7,4.0),5.37(1H,d,J 9.2,NH),5.15(1H, s,lipid-H-3),5.03(1H,t,J 9.7,H-3),4.81–4.71(4H,m,H-1,NapCH₂,Troc),4.63(1H,d,J 11.9,Troc), 3.81(2H,qd,J 10.5,3.8,H-6),3.69(1H,t,J 9.8,H-4),3.65–3.54(2H,m,H-2,H-5),3.47(1H,s,OH), 2.62–2.48(2H,m,lipid-H-2),2.28(2H,t,J 7.3,lipid’-H-2),1.57(4H,s,lipid’-H-3,lipid-H-4),1.25(34H, s),0.88(15H,s),0.12(6H,d,J 17.5).

δ_C(101MHz,CDCl₃)174.35,171.77,154.27,135.54,133.29,133.02,128.20,127.89,127.71,126.29, 126.11,125.88,125.56,96.50(C-1),75.91(C-3),74.72(C-5),74.61,73.73,70.96,70.19(C-4),70.01(C-6), 60.43,57.85(C-2),40.10,34.58,34.50,31.94,29.65,29.56,29.52,29.37,29.30,29.14,25.61,25.16,24.99, 22.71,21.06,17.93,14.21,14.14,-4.06,-5.28.

EXAMPLE 5 preparation of Compound 4

(1)

The compound 3-a (0.5g,0.489mmol) and tetrazole (102mg,1.45mmol,3eq) were dissolved in extra dry acetonitrile (10mL), allyl ligand (hexadiene-N, N-diisopropylphosphoramidite, 0.24g,0.978mmol,2eq) was added, and the reaction was carried out at room temperature for 40min, after which the starting material was consumed.

mCPBA (211mg,1.22mmol,2.5eq) was dissolved in super dry dichloromethane (15mL) at-40 ℃, the reaction system was added, slowly warmed to-10 ℃, quenched with saturated sodium thiosulfate solution (20mL) after 40min of reaction, washed with saturated sodium bicarbonate (40mL), and purified by dry spin-dry silica gel column chromatography (petroleum ether: ethyl acetate ═ 8:1) to give compound 4-a (0.53g, 92%). TOF-MS M/z 1198.67[ M + Na ]]⁺.

δ_H(400MHz,CDCl₃)7.85–7.77(4H,m),7.50–7.44(3H,m),5.90–5.73(2H,m,CH₂＝CH-CH₂O-), 5.41–5.16(6H,m,NH,lipid-H-3,CH₂＝CH-CH₂O-),4.97(1H,d,J 7.9,H-1),4.79-4.63(4H,td,J 12.3,12.4,12.0,Troc,Nap-CH₂),4.49–4.38(5H,m,H-4,CH₂＝CH-CH₂O-),3.85(1H,d,J 9.6,H-6),3.75(1 H,d,J 5.4,H-6),3.72–3.65(1H,m,H-5),3.50–3.40(1H,m,H-2),2.64–2.60(2H,m),2.28(2H,t,J 7.4),1.58(4H,br,J 7.3),1.25(34H,s),0.91–0.86(15H,m),0.13(6H,d,J 19.2).

δ_C(101MHz,CDCl₃)173.57,170.37,153.95,135.65,133.27,132.98,132.27,132.21,132.14,128.09, 127.87,127.68,126.23,126.05,125.81,125.65,118.56,118.40,95.63(C-1),95.32,74.59,74.12(C-5), 74.06(C-4),73.61,72.42(C-3),70.06,68.70(C-6),68.62,68.56,68.46,68.41,58.67(C-2),39.59,34.51,34.24, 31.92,29.66,29.64,29.57,29.52,29.35,29.20,25.61,25.17,25.07,22.69,22.57,17.93,14.12,-4.15,-5.25.

(2)

Dissolving the compound 3-a (0.5g,0.489mmol) and tetrazole (102mg,1.45mmol,3eq) in ultra-dry acetonitrile (10mL), adding allyl ligand (0.18g,0.73mmol,1.5eq), reacting at room temperature for 2h until the raw material is not consumed, supplementing 0.5eq of allyl ligand, and consuming the raw material after 30 min. mCPBA (211mg,1.22mmol,2.5eq) was dissolved in super dry dichloromethane (15mL) at-40 ℃, added to the reaction system, slowly raised to-10 ℃, quenched after 30min reaction with saturated sodium thiosulfate solution (20mL), washed with saturated sodium bicarbonate (40mL), and purified by dry spin-dry silica gel column chromatography (petroleum ether: ethyl acetate ═ 8:1) to give compound 4-a (0.49g, 84.7%).

(3)

Dissolving the compound 3-a (0.5g,0.489mmol) and tetrazole (171mg,2.45mmol,5eq) in ultra-dry acetonitrile (10mL), adding allyl ligand (0.24g,0.978mmol,2eq), reacting at room temperature for 40min until the raw material is consumed, dissolving mCPBA (211mg,1.22mmol,2.5eq) in ultra-dry dichloromethane (15mL) at-40 ℃, adding the reaction system, slowly raising the temperature to-10 ℃, quenching after 40min, adding saturated sodium thiosulfate solution (20mL), washing with saturated sodium bicarbonate (40mL), and purifying by dry spin-drying silica gel column chromatography (petroleum ether: ethyl acetate 8:1) to obtain the compound 4-a (0.474g, 82.3%).

EXAMPLE 6 preparation of Compound 5-a

Compound 4-a (0.8g,0.68mmol) was dissolved in THF (24mL), HF/pyridine (2.4mL, 65-70%) diluted in 15mL pyridine was added at-40 ℃. Slowly heating to room temperature for reaction for 12h, and using NaHCO to react reaction liquid₃(40mL) quench and add CH₂Cl₂(50mL), and drying, spin-drying and purifying by silica gel column chromatography (petroleum ether: ethyl acetate ═4:1) to obtain the compound 5-a (0.657g, 91%, white solid). TOF-MS M/z 1084.48[ M + Na ]]⁺。

δ_H(400MHz,CDCl₃)7.85–7.77(4H,m),7.51–7.44(3H,m),5.91–5.65(2H,m,CH₂＝CH-CH₂O-), 5.61(1H,d,J 9.4,NH),5.42–5.26(3H,m,H-1,CH₂＝CH-CH₂O-),5.23–5.09(4H,m,H-3,CH₂＝CH- CH₂O-,lipid-H-3),4.80-4.69(4H,m,Troc,Nap-CH₂),4.45–4.40(3H,m,H-4,CH₂＝CH-CH₂O-),4.36– 4.27(2H,m,CH₂＝CH-CH₂O-),4.25–4.19(1H,m,H-5),4.01–3.94(1H,m,H-2),3.84–3.75(2H,m,H- 6),2.60(2H,ddd,J 21.4,16.2,6.3),2.24(2H,t,J 7.6),1.56(4H,d,J 7.0),1.25(34H,s),0.88(6H,t,J 6.8).

δ_C(101MHz,CDCl₃)173.38,170.76,154.31,135.19,133.23,133.04,132.28,132.22,132.09,132.02, 128.23,127.92,127.70,126.67,126.15,125.95,125.81,118.66,118.38,95.37,91.50(C-1),74.65,73.63(C- 4),70.82(C-3),69.90,69.57,69.52(C-5),68.67,68.61,68.47,68.40,68.35(C-6),54.27(C-2),39.10,34.46, 34.15,31.92,29.64,29.57,29.53,29.36,29.32,29.18,25.18,25.01,22.69,14.12.

EXAMPLE 7 preparation of Compound 6-a

Compound 5-a (1.3g,1.22mmol) was dissolved in ultra dry (dry) CH₂Cl₂(20mL)，N₂2,2, 2-trifluoro-N-phenylacetylimine chloride (1.52g,7.32mmol, 6eq) and DBU (371mg,2.44mmol, 2eq) were added under protection and reacted at room temperature for 30 mins. The reaction was purified by column chromatography (petroleum ether: ethyl acetate 15:1with 0.1% Et)₃N) gave compound 6-a (1.11g, 74%, colorless syrup). TOF-MS M/z 1255.48[ M + Na ]]⁺。

EXAMPLE 8 preparation of Compound 7

(1)

Compound 1(3.39g,5.58mmol) and compound 20(4.29g,11.16mmol,2eq) were added to a reaction flask, after addition of 40mL of dichloromethane, EDC · HCl (2.14g,11.16mmol,2eq) and DMAP (135mg,1.1mmol,0.2eq) were added under ice-bath, and compound 1 was consumed after stirring at room temperature for 3 h. Saturated sodium bicarbonate solution (25mL) was added to wash the separated liquid, dried, filtered, dried and purified by recrystallization (dichloromethane: methanol ═ 1: 12) to obtain compound 7(5.08g, 93.5%). TOF-MS M/z 994.41[ M + Na ]]⁺。

δ_H(400MHz,CDCl₃)7.81(1H,s),7.76–7.61(7H,m),7.48–7.35(5H,m),7.30(1H,d,J 8.4),5.50 (1H,s,NapCH),5.39(1H,t,J 9.9,H-3),5.24(1H,d,J 9.1,NH),4.84(1H,d,J 7.8,H-1),4.67–4.62(3H, m,NapCH_2,-OCH₂CCl₃),4.52(1H,d,J 11.8,-OCH₂CCl₃),4.31(1H,dd,J 10.4,4.7,H-6),3.85–3.81(1H, m,Lipid-H-3),3.78(1H,d,J 10.3,H-6),3.71(1H,t,J 9.5,H-4),3.67–3.60(1H,m,H-2),3.53(1H,td,J 9.5,5.1,H-5),2.74(1H,dd,J 14.9,6.0,Lipid-H-2),2.55(1H,dd,J 14.8,5.6,Lipid-H-2),1.54(2H,m, Lipid-H-4),1.27(18H,s),0.91(12H,s),0.13(6H,d,J 12.0).

δ_C(101MHz,CDCl₃)171.82,154.36,136.11,134.41,133.85,133.41,133.13,132.99,128.53,128.28, 128.23,128.11,127.88,127.85,126.60,126.51,126.31,126.20,126.04,125.96,125.91,123.85,101.88,97.14 (C-1),79.18(C-4),75.73(C-6),74.88,71.39(C-3),71.28,68.91(C-6),66.76(C-5),60.64,59.29(C-2),39.77, 34.71,32.15,29.87,29.86,29.80,29.77,29.58,25.74,25.45,22.92,21.28,18.08,14.43,14.37,-3.98,-5.08.

(2)

EDC & HCl (1.087g,5.67mmol,1.2eq), compound 20(2.18g,5.67mmol,1.2eq) was added to a reaction flask, 25mL of dichloromethane was added, and after stirring at room temperature for 15min, compound 1(2.87g,4.72mmol), DMAP (29mg,0.237mmol, 0.05eq) were added and the reaction was continued for 12h with compound 1 being unconsumed. Saturated sodium bicarbonate solution (25mL) was added to wash the separated liquid, dried, filtered, dried and purified by column chromatography (petroleum ether: ethyl acetate: 7: 1) to obtain compound 7(2.72g, 59.23%).

(3)

EDC & HCl (1.81g,9.44mmol,2eq), compound 20(2.54g,6.6mmol,1.4eq) were added to a reaction flask, 25mL of dichloromethane was added, and after stirring at room temperature for 15min, compound 1(2.87g,4.72mmol), DMAP (29mg,0.237mmol, 0.05eq) were added and the reaction was continued for 12h with compound 1 unconsumed. Saturated sodium bicarbonate solution (25mL) was added to wash the separated liquid, dried, filtered, dried and purified by column chromatography (petroleum ether: ethyl acetate: 7: 1) to obtain compound 7(3.27g, 71.2%).

(4)

EDC & HCl (2.65g,13.8mmol,2eq) and compound 20(5.33g,13.8mmol,2eq) were added to a reaction flask, 50mL of dichloromethane was added, and after stirring at room temperature for 15min, compound 1(4.12g,6.78mmol), DMAP (170mg,1.39mmol,0.2 eq) were added and the reaction was run for 12h with compound 1 being consumed. Saturated sodium bicarbonate solution (50mL) was added to wash the separated liquid, dried, filtered, dried and purified by column chromatography (petroleum ether: ethyl acetate: 7: 1) to obtain compound 7(5.22g, 79.1%).

(5)

Compound 1(3.39g,5.58mmol) and compound 20(4.29g,11.16mmol,2eq) were added to a reaction flask, after addition of 40mL of dichloromethane, EDC · HCl (2.14g,11.16mmol,2eq) and DMAP (135mg,1.1mmol,0.2eq) were added under ice-bath, and compound 1 was consumed after stirring at room temperature for 3 h. Saturated sodium bicarbonate solution (25mL) was added to wash the separated liquid, dried, filtered, dried and purified by column chromatography (petroleum ether: ethyl acetate: 7: 1) to obtain compound 7(4.71g, 86.7%).

(6)

Compound 1(3.39g,5.58mmol) and compound 20(4.29g,11.16mmol,2eq) were added to a reaction flask, after addition of 40mL of dichloromethane, EDC · HCl (2.14g,11.16mmol,2eq) and DMAP (135mg,1.1mmol,0.2eq) were added under ice-bath, and compound 1 was consumed after stirring at room temperature for 3 h. Saturated sodium bicarbonate solution (25mL) was added to wash the separated liquid, dried, filtered, dried and purified by recrystallization (dichloromethane: methanol ═ 1: 8) to obtain compound 7(3.93g, 72.4%).

EXAMPLE 9 preparation of Compound 8

Compound 7(6g,6.16mmol) was dissolved in methylene chloride (60mL), and acetic acid (12mL,2V) and zinc powder (6g,1V) (V means mass equivalent) were added thereto, and the mixture was stirred vigorously at room temperature for 2 hours to complete the reaction, followed by washing with saturated sodium bicarbonate (60mL) and saturated brine (60 mL). Separation, drying and concentration gave compound 8(5.3 g). TOF-MS M/z 821.134[ M + Na ]]⁺. Directly used for the next reaction.

EXAMPLE 10 preparation of Compound 9

(1)

Compound 8 prepared in example 9 was dissolved in dichloromethane (100mL), FmocCl (3.2g,12.36mmol,2eq) and DIPEA (1.6g,12.36mmol,2eq) were added under ice bath, the reaction was completed by stirring at room temperature for 2h, and the mixture was washed with saturated brine (100mL), separated, dried and recrystallized (dichloromethane: methanol 1: 10) to obtain compound 9(5.6g, 89.1%). TOF-MS M/z 1042.7[ M + Na ]]⁺。

δ_H(400MHz,CDCl₃)7.83(1H,s),7.78–7.65(7H,m),7.64–7.44(5H,m),7.40(6H,ddd,J 15.3, 9.7,5.3),7.32–7.24(3H,m),5.53(1H,s,NapCH),5.44(1H,t,J 9.4,H-3),4.97(1H,d,J 8.7,NH),4.91 (1H,d,J 7.2,H-1),4.63(1H,d,J 11.8,Fmoc-CH₂),4.51(1H,d,J 11.8,,Fmoc-CH₂),4.32(1H,br,H-6), 4.28(2H,d,J 6.5,NapCH₂),4.17(1H,d,J 6.4,,Fmoc-CH),3.82(2H,s,H-6,Lipid-H-3),3.78–3.71(1H, m,H-4),3.67(1H,d,J 8.9,H-2),3.58(1H,br,H-5),2.70(1H,dd,J 14.8,6.3),2.50(1H,dd,J 14.8,5.5), 1.55–1.37(2H,m),1.29–0.96(18H,m),0.91–0.81(12H,m),0.09(6H,d,J 13.5).

δ_C(101MHz,CDCl₃)155.78,143.79,141.23,135.92,134.24,133.63,133.17,132.87,132.78,128.31, 128.05,127.92,127.86,127.63,127.04,126.34,126.26,126.06,125.93,125.81,125.69,125.15,123.64, 119.96,101.65,97.14(H-1),79.00(H-4),75.62(H-6),71.25(H-3),71.19,68.76(H-6),67.19,66.60(H-5), 58.98(H-2),47.04,39.74,34.53,31.92,29.61,29.53,29.34,25.49,25.16,22.69,17.86,14.14,-4.21,-5.36.

(2)

Compound 7(6g,6.16mmol) was dissolved in methylene chloride (60mL), acetic acid (12mL,2V) and zinc powder (6g,1V) were added, the mixture was stirred vigorously at room temperature for 2 hours, and the reaction was completed, followed by saturated sodium bicarbonate (60mL) and saturated brine (60 mL). Separation, drying and concentration gave compound 8(5.3 g). This was dissolved in dichloromethane (100mL), FmocCl (3.2g,12.36mmol,2eq), DIPEA (1.6g,12.36mmol,2eq) were added under ice-bath, the reaction was completed by stirring at room temperature for 2h, and the mixture was washed with saturated brine (100mL), dried by liquid separation and then recrystallized (methanol, 5V) to obtain compound 9(4.91g, 78.1%).

EXAMPLE 11 preparation of Compound 10

Compound 9(1.5g,1.47mmol) is reacted with molecular sieves (b), (d)

1.5g) in ultra-dry CH₂Cl₂(60mL)，N₂Triethylsilane (0.55mL,3.67mmol,2.5eq) and PhBCl were added at-78 ℃ under protection₂(0.76mL,5.88mmol) and the reaction was stirred at-78 deg.C for 1 h. After the reaction is finished, methanol (6mL) is added for quenching, and the pH value is adjusted to 8 by triethylamine. The reaction solution was filtered and then saturated NaHCO₃(10mL) washing. Dry spin-dry silica gel column chromatography (petroleum ether: ethyl acetate ═ 6:1) afforded compound 10(1.2g, 80.1%, colorless oily liquid). TOF-MS M/z 1044.45[ M + Na ]]⁺。

δ_H(400MHz,CDCl₃)7.75–7.73(1H,m),7.70(7H,dd,J 14.7,5.4),7.66(2H,d,J 5.3),7.62(2H,d, J 5.8),7.53(1H,d,J 3.9),7.44–7.38(6H,m),7.30–7.25(3H,m),5.32(1H,t,J 9.8,H-3),4.93(1H,d,J 9.3,NH),4.79(1H,d,J 6.6,H-1),4.73(2H,q,J 11.7,NapCH₂),4.57(2H,dd,J 24.5,11.7,Fmoc-CH₂), 4.24(2H,d,J 7.1,Lipid-NapCH₂),4.17–4.10(1H,m,Fmoc-CH),3.85-3.80(2H,s,H-6,Lipid-H-3),3.74 (1H,d,J 3.9,H-4),3.73–3.69(1H,m,H-6),3.60(1H,dd,J 18.4,9.4,H-2),3.49(1H,d,J 8.3,H-5),2.55 (1H,dd,J 15.6,7.1),2.39(1H,dd,J 15.5,4.9),1.55–1.39(2H,m),1.22–1.06(18H,m),0.87–0.82(12 H,m),0.08(6H,d,J 13.4).

δ_C(101MHz,CDCl₃)172.00,155.84,143.86,141.23,135.99,135.05,133.23,133.15,132.98,132.92, 128.26,128.04,127.95,127.87,127.69,127.65,127.04,126.67,126.29,126.14,126.00,125.97,125.87, 125.79,125.74,125.22,119.96,96.66(H-1),75.72(H-4),75.28(H-5),74.64(H-3),71.47(Fmoc-CH₂),67.24 (Lipid-NapCH₂),62.00(H-6),58.48(H-2),53.46,47.06(Fmoc-CH),39.74,34.19,31.96,29.67,29.65,29.62, 29.60,29.38,25.52,25.15,22.73,17.90,14.17,-4.07,-5.25.

EXAMPLE 12 preparation of Compound 11

(1)

The reaction flask was charged with acceptor compound 10(606mg,0.593mmol), donor compound 6-a (1.1g,0.89mmol,1.5eq) molecular sieve (S) ((R))

600mg)，N₂Adding ultra-dry CH under the condition₂Cl₂(10mL), 100-fold dilution of TfOH (10. mu.L, 0.12mmol, 0.2eq) with dichloromethane at-20 ℃ and stirring for 40min at-20 ℃; quench with methanol (5mL) and triethylamine to pH 8. CH for reaction solution₂Cl₂(35mL) and saturated NaHCO₃(10mL) washing. The organic phase was concentrated by drying and purified by column chromatography (PE: EA ═ 10:1) to give the glycosidated product 11-a (1.03g, 84%). TOF-MS M/z 2088.14[ M + Na ]]⁺。

δ_H(400MHz,CDCl₃)7.80–7.21(29H,m),5.89–5.68(2H,m,diallyl),5.48(1H,d,J 7.0,NH’),5.37 (1H,t,J 9.6,H-3’),5.32–5.10(6H,m,H-3,lipid-H-3,diallyl),4.87(1H,d,J 9.1,NH),4.80(1H,d,J 7.7, H-1’),4.74(1H,d,J 3.3,H-1),4.70(4H,d,J 12.8,Troc,Nap),4.64(2H,d,J 3.3,Nap-CH₂),4.53(2H,dd, J 29.1,11.9,Fmoc),4.45(1H,s,H-4’),4.43–4.31(5H,m,H-4,diallyl),4.24(2H,d,J 6.8,acceptor-lipid- Nap),4.16–4.11(1H,m,Fmoc-CH),4.07(1H,d,J 10.3,H-6),3.83(2H,d,J 10.2,H-6,acceptor-lipid-H- 3’),3.72(2H,dd,J 10.3,6.0,H-6’),3.65–3.54(3H,m,H-2,H-5,H-5’),3.41(1H,dd,J 17.7,8.4,H-2’), 2.61(2H,t,J 6.6),2.50(1H,dd,J 15.6,7.1),2.35(1H,dd,J 15.8,5.1),2.28(2H,t,J 7.4),1.59(6H,d,J 7.7),1.42(4H,ddd,J 14.5,10.8,6.1),1.32–1.21(52H,m),0.86(18H,dd,J 14.9,7.8),0.15–0.05(6H, m).

δ_C(101MHz,CDCl₃)δ172.65,170.83,169.04,154.72,152.94,142.82,140.16,134.94,134.60,134.29, 132.19,132.15,132.08,131.91,131.84,131.82,131.29,131.22,131.13,131.06,129.85,127.80,127.12, 127.06,126.93,126.85,126.79,126.62,126.60,126.55,125.97,125.32,125.17,125.10,125.02,124.90, 124.85,124.78,124.70,124.67,124.61,124.18,118.86,117.44,117.27,99.00(C-1’),95.53(C-1),94.38, 75.08(C-5’),74.58(C-5)73.71(C-3),73.43(C-4’),73.31(C-4),73.11,73.05,72.96,72.91,72.60,71.37(C-3’), 70.37,69.10,67.55(C-6),67.49(C-6’),67.34,67.28,66.14,64.51,57.32(C-2),55.78(C-2’),46.00,38.78, 38.64,33.50,33.41,33.13,30.89,28.67,28.63,28.61,28.59,28.54,28.51,28.31,28.17,24.54,24.15,24.07, 24.03,21.66,18.16,16.82,13.12,13.10,-4.91,-6.31.

(2)

Compound 6-a (50mg,0.04mmol) and compound 10(51mg,0.049mmol,1.2eq) were charged to a reaction flask, 1mL of ultra dry dichloromethane was added under nitrogen protection, and 100 fold diluted TfOH (0.25mg,0.00167mmol, 0.05eq) was added at-20 ℃. After 1h compound 6-a (donor) was consumed and compound 10 (acceptor) was not consumed. Methanol is added to quench triethylamine and adjust to be neutral. Purification by column chromatography (toluene: ethyl acetate ═ 12: 1) gave compound 11-a (49mg, 58.5%). Since the product 11-a is close in polarity to the acceptor 10, it is more polar than the donor 6-a. Therefore, when the acceptor 10 is excessive, the isolated yield is low although the reaction conversion rate is substantially equivalent.

(3)

Compound 6-a (100mg,0.081mmol, 1.2eq) and compound 10(69mg,0.067mmol) were charged into a reaction flask, 1mL of ultra dry dichloromethane was added under nitrogen protection, and 100-fold diluted TfOH (0.5mg,0.0033mmol, 0.05eq) was added at-20 ℃. After 1h, the donor acceptor is not consumed, and the reaction time is not changed after the reaction is prolonged. Methanol is added to quench triethylamine and adjust to be neutral. Purification by column chromatography (toluene: ethyl acetate ═ 12: 1) gave compound 11-a (58mg,0.0278mmol, 41.7%).

(4)

Compound 6-a (200mg,0.162mmol, 1.5eq) and compound 10(110mg,0.107mmol) were charged to a reaction flask, 1mL of ultra dry dichloromethane was added under nitrogen protection, and TfOH (0.8mg,0.0053mmol, 0.05eq) diluted 100-fold was added at-20 ℃. After 1h, the donor acceptor is not consumed, and the reaction time is not changed after the reaction is prolonged. Methanol is added to quench triethylamine and adjust to be neutral. Purification by column chromatography (toluene: ethyl acetate ═ 12: 1) gave compound 11-a (107mg, 48.2%).

(5)

Compound 6-a (200mg,0.162mmol, 1.5eq) and compound 10(110mg,0.107mmol) were charged to a reaction flask, 1mL of ultra dry dichloromethane was added under nitrogen protection, and TfOH (2.43mg,0.0162mmol, 0.15eq) diluted 100-fold was added at-20 ℃. The donor was consumed after 1 h. Methanol is added to quench triethylamine and adjust to be neutral. Purification by column chromatography (toluene: ethyl acetate ═ 12: 1) gave compound 11-a (192mg, 86.48%). TOF-MS M/z 2088.14[ M + Na ]]⁺。

EXAMPLE 13 preparation of Compound 12-a

Compound 11-a (860mg,0.029mmol) is dissolved in CH in a reaction flask₂Cl₂(10mL)，N₂Under the conditions, zinc powder (2.7g, 40mmol) and acetic acid (2.7mL, 45mmol) were added and stirred at room temperature for 2h, after completion of the reaction, the reaction mixture was filtered, and the filtrate was azeotropically dried with toluene and subjected to column chromatography (PE: EA ═ 6:1) to give compound 12-a. TOF-MS M/z 1912.06[ M + Na ]]⁺。

EXAMPLE 14 preparation of Compound 13-a (MPL-8)

Compound 12-a, prepared in example 13, was dissolved in ultra dry DCM (10mL), N₂EDC & HCl (2g,10.43mmol) and aliphatic chain 19-A (1.48g,3.47mmol) were added at-10 deg.C, the reaction stirred for 12h and purified by spin-dry column chromatography (toluene/ethyl acetate 10:1) to give compound 13-a (680mg, 71%, colorless clear syrup). TOF-MS M/z 2323.15[ M + Na ]]⁺。

EXAMPLE 15 preparation of Compound 14-a

Compound 13-a (580mg,0.252mmol) was dissolved in DMF (12mL), N in a reaction flask₂Triethylamine (12mL, 86mmol) was added under these conditions, the mixture was stirred at room temperature overnight, and the reaction mixture was purified by column chromatography (PE: EA ═ 6:1) by spin drying to give compound 14-a. TOF-MS M/z 2030.2[ M + Na ]]⁺。

EXAMPLE 16 preparation of Compound 15-a

Compound 14-a, prepared in example 15, is dissolved in ultra dry CH₂Cl₂(5mL)，N₂EDC · HCl (295mg,1.53mmol) and aliphatic chain 20(296mg,0.77mmol) were added at room temperature, the reaction mixture was stirred at room temperature for 12h, and purified by spin-dry column chromatography (toluene/ethyl acetate ═ 5:1) to give compound 15-a (480mg, yield 78%, colorless transparent syrup). TOF-MS M/z 2468.4[ M + Na ]]⁺。

EXAMPLE 17 preparation of Compound 16-a

Compound 15-a (300mg, 0.123mmol) was dissolved in THF (10mL), and a solution of HF/Py (3mL, 65-70%) in pyridine (9mL) was added at-40 ℃. Warmed to room temperature and stirred overnight. After the reaction, saturated aqueous sodium bicarbonate solution was added to quench, and chloroform was added to extract the solution several times. The organic layer was dried, filtered and concentrated and purified by a C18 packing (CH)₃CN, MeOH/EA ═ 8:1, MeOH eluting sequentially) gave 16-a (0.214g, 75%, white solid).

δ_H(600MHz,CDCl₃)7.77–7.24(28H,m),6.28(1H,d,J 9.5,NH),6.22(1H,d,J 7.4,NH’),5.77–5.70(1H,m,allyl),5.67–5.59(1H,m,allyl),5.44–5.31(3H,m,H-3,H-1’,H-3’),5.22–5.03(6H,m, allyl,H-1,lipid-H-3),4.99(1H,t,J 5.8,lipid-H-3),4.67–4.57(5H,m,Nap),4.52–4.42(3H,m,Nap), 4.35–4.21(5H,m,H-4’,diallyl),4.17(1H,td,H-2),4.05(1H,d,J 7.2,H-5),3.87(1H,d,J 11.7,H-6’), 3.80–3.74(3H,m,lipid-H-3*2,H-6’),3.67–3.56(4H,m,H-4’,H-6*2,H-5’),3.32–3.28(1H,m,H-2’), 3.27(1H,t,J 11.6,7.7,H-4),2.55–2.43(3H,m),2.28–2.11(9H,m),1.45–1.37(8H,m),1.22–1.10 (108H,m),0.80(18H,dt,J 7.0,5.1).

δ_C(151MHz,CDCl₃)173.28,172.55,170.87,170.29,169.85,168.98,135.06,134.48,133.92,132.31, 132.23,132.19,132.10,131.96,131.90,131.86,131.22,131.17,131.11,131.06,127.15,127.09,127.05, 126.91,126.83,126.66,126.57,125.46,125.41,125.36,125.24,125.06,124.99,124.93,124.88,124.85, 124.82,124.73,124.64,124.61,117.45,117.30,98.02(C-1’),90.43(C-1),75.46(C-4),74.52,73.50,73.23, 73.09,72.86(C-5’),72.51(C-3),71.64(C-3’),70.60(C-5),70.36,69.75,69.33,67.55(C-4’),67.51,67.28(C- 6’),67.24,66.43(C-6),59.37,55.37(C-2’),51.48(C-2),41.01,40.61,38.95,38.86,33.63,33.54,33.40,33.34, 30.92,28.64,28.56,28.35,28.21,24.17,24.06,23.89,21.67,13.09.

EXAMPLE 18 preparation of Compound 17-a

(1)

The compound 16-a (240mg, 0.103mmol), PPh₃(25mg,0.095mmol) was added to the flask, THF (10mL), TEA were added under nitrogen(125μL,0.9mmol),HCOOH(75μL,1.957mmol),Pd(Ph₃)₄(25mg,0.02mmol, 0.2 eq). Reacting at 25 deg.C for 5 hr, reacting for 12 hr, removing allyl, and spin-drying on C18 column CH₃CN with 0.1％TEA,MeOH with 0.1％TEA,CH₂Cl₂MeOH eluting sequentially with 0.1% TEA afforded compound 17-a (184mg, 79.65%).

(2)

The compound 16-a (240mg, 0.103mmol), PPh₃(50mg,0.190mmol) was added to the reaction flask, and after nitrogen blanketing, THF (10mL), TEA (250. mu.L, 1.8mmol), HCOOH (150. mu.L, 3.914mmol), Pd (Ph) were added₃)₄(50mg,0.043mmol, 0.4 eq). After the reaction is completed for 1.5h at 25 ℃, the reaction solution is spun through a C18 column CH₃CN with 0.1％TEA,MeOH with 0.1％TEA, CH₂Cl₂MeOH with 0.1% TEA afforded compound 17-a (225mg, 97.4%). TOF-M: M/z:2248.76[ M-H]⁺。

When PPh contains two equivalents of allyl per molecule₃And other agents in conventional amounts (e.g., PPh)₃A molar ratio to allyl of about 0.9:1 to 1.1: 1), compound 17 can be obtained in high yield.

EXAMPLE 19 preparation of Compound 18-a

(1)

The compound 17-a (50mg,0.022mmol) and DDQ (1.1g,4.84mmol,220eq) were added to a reaction flask, and dried CHCl was added under nitrogen protection₃(5 mL). And (3) finishing the reaction after ultrasonic treatment at 30 ℃ for 60 min. Quench with a drop of triethylamine and spin dry the reaction. Acetonitrile was added to the spin-dried reaction flask, and the mixture was poured into a column chromatography packed with C18 to decolorize and purify the mixture. When the excess DDQ is completely removed, CH₂Cl₂MeOH ═ 3:1 gave compound 18-a (25mg, 67.6%) as the final product. (since DDQ is greatly beyond the conventional amount, in the case of a small feed scale, although the reaction yield can reach the theoretical value, a large amount of residual DDQ affects the yield of the post-treatment purification)

(2)

The compound 17-a (50mg,0.022mmol) and DDQ (10mg,0.044mmol,2eq) were added to a reaction flask, and dried CHCl was added under nitrogen protection₃(5 mL). And (3) finishing the reaction after ultrasonic treatment at 30 ℃ for 60 min. Quench with a drop of triethylamine and spin dry the reaction. Acetonitrile was added to the spin-dried reaction flask, and the mixture was poured into a column chromatography packed with C18 to decolorize and purify the mixture. When the excess DDQ is completely removed, CH₂Cl₂MeOH ═ 3:1 gave compound 18-a (17mg, 45.9%) as the final product. As in (4), the yield can be greatly improved by prolonging the reaction time.

(3)

The compound 17-a (50mg,0.022mmol) and DDQ (40mg,0.177mmol, 8eq) were added to a reaction flask, and dried CHCl was added under nitrogen protection₃(5 mL). The reaction is completed after 30 ℃ ultrasonic treatment for 60 min. Quench with a drop of triethylamine and spin dry the reaction. Acetonitrile was added to the spin-dried reaction flask, and the mixture was poured into a column chromatography packed with C18 to decolorize and purify the mixture. When the excess DDQ is completely removed, CH₂Cl₂MeOH ═ 3:1 gave compound 18-a (29mg, 78.4%) as the final product. As in (4), the yield can be greatly improved by prolonging the reaction time.

(4)

The compound 17-a (50mg,0.022mmol) and DDQ (40mg,0.177mmol, 8eq) were added to a reaction flask, and dried CHCl was added under nitrogen protection₃(5 mL). The reaction is completed after 30 ℃ ultrasonic treatment for 80 min. Quench with a drop of triethylamine and spin dry the reaction. Acetonitrile was added to the spin-dried reaction flask, and the mixture was poured into a column chromatography packed with C18 to decolorize and purify the mixture. When the excess DDQ is completely removed, CH₂Cl₂MeOH ═ 3:1 gave compound 18-a (35.8mg, 95.26%, HPLC purity: 98.5%) as a final product. TOF-MS M/z 1689.36[ M-H ]]⁺。

Examples of Compound 18-b series

EXAMPLE 20 preparation of Compound 13-b

In a reaction flask, 11-a (400mg,0.194 mmol)) Dissolved in CH₂Cl₂(5mL)，N₂Adding zinc powder 1.2g) and acetic acid (1.2 mL) under the condition, stirring at room temperature for 2h, filtering after the reaction is finished, performing azeotropic spin-drying on the filtrate by using toluene and performing column chromatography (PE: EA is 6:1) to obtain a compound 12-a (TOF-MS: M/z 1915.49[ M + Na & lt/EN & gt verified by MS)]⁺)

Compound 12-a was dissolved in ultra dry DCM (5mL), N₂EDC & HCl (0.892g,4.656mmol) and fatty chain 19-C (749mg,1.552mmol) (cas:93390-37-5) were added at-10 deg.C, the reaction was stirred for 12h and then purified by spin-column chromatography (toluene/ethyl acetate ═ 10:1) to give compound 13-b (722.7mg, 63.4%, colorless clear syrup). TOF-MS M/z 2380.26[ M + Na ]]⁺。

EXAMPLE 21 preparation of Compound 14-b

Compound 13-b (600mg,0.254mmol) was dissolved in DMF (12mL), N in a reaction flask₂Triethylamine (12mL) was added under these conditions, stirred at room temperature overnight, and the reaction was purified by column chromatography (PE: EA ═ 6:1) to give compound 14-b (verified by MS). TOF-MS M/z 2158.02[ M + Na ]]⁺。

EXAMPLE 22 preparation of Compound 15-b

Dissolving Compound 14-b in SuperDry CH₂Cl₂(5mL)，N₂EDC · HCl (390.35mg,2.036mmol) and fatty chain 20(390.7mg,1.016mmol) were added at room temperature, the reaction mixture was stirred at room temperature for 12h, and purified by spin-dry column chromatography (toluene/ethyl acetate ═ 5:1) to give compound 15-b (504mg, 79.3% colorless clear syrup). TOF-MS M/z 2524.56[ M + Na ]]⁺。

EXAMPLE 23 preparation of Compound 16-b

Compound 15-b (500mg,0.2 mmol) was dissolved in THF (18mL), and a solution of HF/Py (5mL, 65-70%) in pyridine (15mL) was added at-40 ℃. Warm to room temperature and stir overnight. After the reaction, saturated aqueous sodium bicarbonate solution was added to quench, and chloroform was added to extract the solution several times. The organic layer was dried, filtered and concentrated and purified by a C18 packing (CH)₃CN, MeOH/EA ═ 8:1, MeOH) gave 16-b (0.351g, 73.5%, white solid). TOF-MS M/z 2410.34[ M + Na ]]⁺。

EXAMPLE 24 preparation of Compound 17-b

The compound 16-b (470mg, 0.196mmol), PPh₃(90mg,0.370mmol) was added to the reaction flask, and after nitrogen blanketing, THF (20mL), TEA (490. mu.L, 3.5mmol), HCOOH (290. mu.L, 7.8mmol), Pd (Ph) were added₃)₄(90mg,0.08 mmol). After the reaction is completed for 1.5h at 25 ℃, the reaction solution is spun through a C18 column CH₃CN with 0.1％TEA,MeOH with 0.1％TEA,CH₂Cl₂MeOH with 0.1% TEA afforded compound 17-b (428mg, 94.3%). TOF-M: M/z:2330.16[ M + Na ]]⁺。

EXAMPLE 25 preparation of Compound 18-b

The compound 17-b (90mg,0.039mmol) and DDQ (71mg,0.312mmol, 8eq) were added to a reaction flask, and dried CHCl was added under nitrogen protection₃(10 mL). The reaction is completed after 30 ℃ ultrasonic treatment for 80 min. Quench with a drop of triethylamine and spin dry the reaction. Acetonitrile was added to the spin-dried reaction flask, and the mixture was poured into a column chromatography packed with C18 to decolorize and purify the mixture. When the excess DDQ is completely removed, CH₂Cl₂MeOH ═ 3:1 gave compound 18-b (65mg, 95.26%) as a final product. TOF-MS M/z 1745.47[ M-H ]]⁺. HPLC purity: 97.5 percent.

Examples of the series of Compounds 18-c

EXAMPLE 26 preparation of Compound 2-c

Compound 19-B (cas:163310-36-9) (2.613g,5.93mmol) and EDC & HCl (1.136g,5.93mmol, 1.2eq) were dissolved in CH₂Cl₂(25mL), after stirring at room temperature for 15min, compound 1(3g,4.94mmol) and DMAP (0.03g,0.247mmol, 0.05eq) were added, and the mixture was stirred at room temperature for 10h to complete the reaction, and the reaction solution was successively reacted with CH₂Cl₂(50mL) and saturated NaHCO₃(30mL) washed. The fractions were dried, concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate 10:1) to give compound 2-c (4.29g, 84.3%, colorless syrup). TOF-MS M/z 1052.7[ M + Na ]]⁺。

EXAMPLE 27 preparation of Compound 3-c

Compound 2-c (1g,0.97mmol) was dissolved in THF (10mL) and BH was added sequentially under ice bath conditions₃·Me₃N(0.28g,3.783 mmol，3.9eq)，AlCl₃(0.76g,5.7mmol)，H₂O (35mg,1.92mmol, 1.9eq) the reaction was stirred at room temperature for 1.5 h. Water (10mL) and 1M HCl solution (10mL) were added to quench, and the reaction solution was quenched with CH₂Cl₂(15mL) was separated, dried, concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate 10:1) to give compound 3-c (0.882g, 87.6%, colorless oily liquid). TOF-MS M/z 1059.42[ M + Na ]]⁺.

EXAMPLE 28 preparation of Compound 4-c

Compound 3-c (0.5g,0.482mmol) and tetrazole (102mg,1.45mmol,3eq) were dissolved in extra dry acetonitrile (10mL) and allyl ligand (hexadiene-N, N-diisopropylphosphoramidite, 0) was added.236g,0.964mmol,2eq), after 40min reaction at room temperature the starting material was consumed. mCPBA (207.9mg,1.205mmol,2.5eq) was dissolved in ultra-dry dichloromethane (15mL) at-40 ℃, the reaction system was added, the temperature was slowly raised to-10 ℃, the reaction was quenched by addition of saturated sodium thiosulfate solution (20mL) after 40min, washed with saturated sodium bicarbonate (40mL), and purified by dry spin-dry silica gel column chromatography (petroleum ether: ethyl acetate ═ 8:1) to give compound 4-c (0.537g, 93.3%). TOF-MS M/z 1214.8[ M + Na ]]⁺.

EXAMPLE 29 preparation of Compound 5-c

Compound 4-c (1.5g,1.26mmol) was dissolved in THF (45mL), HF/pyridine (4.8 mL, 65-70%) diluted in 30mL pyridine was added at-40 ℃. Slowly heating to room temperature for reaction for 12h, and using NaHCO to react reaction liquid₃(80mL) quench and add CH₂Cl₂(100mL) and dried by spin-dry silica gel column chromatography (petroleum ether: ethyl acetate 4:1) to give compound 5-c (1.26g, 93.4%, white solid). TOF-MS M/z 1100.53[ M + Na ]]⁺。

EXAMPLE 30 preparation of Compound 6-c

Compound 5-c (1.3g,1.21mmol) was dissolved in ultra-dry CH₂Cl₂(20mL)，N₂2,2, 2-trifluoro-N-phenylacetylimine chloride (1.50g,7.24mmol, 6eq) and DBU (368mg,2.42mmol, 2eq) were added under protection and reacted at room temperature for 30 mins. The reaction was purified by column chromatography (petroleum ether: ethyl acetate 15:1with 0.1% Et)₃N) gave compound 6-c (1.19g, 79%, colorless syrup). TOF-MS M/z 1271.65[ M + Na ]]⁺。

EXAMPLE 31 preparation of Compound 11-c

The reaction flask was charged with acceptor compound 10(700mg,0.684mmol), donor compound 6-c (1.28g,1.026mmol,1.5eq) molecular sieve (1

600mg)，N₂Adding ultra-dry CH under the condition₂Cl₂(10mL), 100-fold dilution of TfOH (20. mu.L, 0.137mmol, 0.2eq) with dichloromethane at-20 ℃ and stirring for 40min at-20 ℃; quench with methanol (5mL) and triethylamine to pH 8. CH for reaction solution₂Cl₂(35mL) and saturated NaHCO₃(10mL) washing. The organic phase was concentrated by drying and purified by column chromatography (PE: EA ═ 10:1) to give the glycosidated product 11-c (1.27g, 89%). TOF-MS M/z 2104.9[ M + Na ]]⁺。

EXAMPLE 32 preparation of Compound 12-c

11-c (500mg,0.24mmol) was dissolved in CH in a reaction flask₂Cl₂(5mL)，N₂Adding zinc powder 1.5g) and acetic acid (15mL) under the condition, stirring at room temperature for 2h, filtering after the reaction is finished, performing azeotropic spin-drying on the filtrate by using toluene and performing column chromatography (PE: EA is 6:1) to obtain a compound 12-c (TOF-MS: M/z 1929.5[ M + Na & lt/EN & gt verified by MS)]⁺)。

EXAMPLE 33 preparation of Compound 13-c

Compound 12-c was dissolved in ultra dry DCM (5mL), N₂EDC & HCl (1.1g,5,76mmol) and fatty chain 19-A (819mg,1.92mmol) were added at-10 ℃ for displacement, the reaction was stirred for 12h, and then purification was performed by spin-dry column chromatography (toluene/ethyl acetate 10:1) to obtain compound 13-c (441mg, 79.4%, colorless clear syrup). TOF-MS M/z 2338.23[ M + Na ]]⁺。

EXAMPLE 34 preparation of Compound 14-c

Compound 13-c (600mg,0.259mmol) was dissolved in DMF (12mL), N in a reaction flask₂Triethylamine (12mL) was added under these conditions, stirred at room temperature overnight, and the reaction was purified by column chromatography (PE: EA ═ 6:1) to give compound 14-c (verified by MS). TOF-MS M/z 2115.9[ M + Na ]]⁺。

EXAMPLE 35 preparation of Compound 15-c

Dissolving Compound 14-c in SuperDry CH₂Cl₂(5mL)，N₂EDC · HCl (397.2mg,2.072mmol) and fatty chain 20(398.4mg,1.036mmol) were added at room temperature, the reaction mixture was stirred at room temperature for 12h, and purified by spin-column chromatography (toluene/ethyl acetate ═ 5:1) to give compound 15-c (518.8mg, 81.4%, colorless clear syrup). TOF-MS M/z 2482.47[ M + Na ]]⁺。

EXAMPLE 36 preparation of Compound 16-c

Compound 15-c (400mg, 0.162mmol) was dissolved in THF (18mL), and a solution of HF/Py (4mL, 65-70%) in pyridine (12mL) was added at-40 ℃. Warm to room temperature and stir overnight. After the reaction, saturated aqueous sodium bicarbonate solution was added to quench, and chloroform was added to extract the solution several times. The organic layer was dried, filtered and concentrated and purified by a C18 packing (CH)₃CN, MeOH/EA ═ 8:1, MeOH) gave 16-c (0.293g, 76.9%, white solid). TOF-MS M/z 2368.26[ M + Na ]]⁺。

EXAMPLE 37 preparation of Compound 17-c

The compound 16-c (459mg, 0.196mmol), PPh₃(90mg,0.370mmol) was added to the reaction flask, and after nitrogen blanketing, THF (20mL), TEA (490. mu.L, 3.5mmol), HCOOH (290. mu.L, 7.8mmol), Pd (Ph) were added₃)₄(90mg,0.08 mmol). After the reaction is completed for 1.5h at 25 ℃, the reaction solution is spun through a C18 column CH₃CN with 0.1％TEA,MeOH with 0.1％TEA,CH₂Cl₂MeOH with 0.1% TEA afforded compound 17-c (405mg, 91.5%). TOF-MS M/z 2288.05[ M + Na ]]⁺。

EXAMPLE 38 preparation of Compound 18-c

The compound 17-c (100mg,0.044mmol) and DDQ (80mg,0.353mmol, 8eq) were added to a reaction flask, and dried CHCl was added under nitrogen protection₃(10 mL). The reaction is completed after 30 ℃ ultrasonic treatment for 80 min. Quench with a drop of triethylamine and spin dry the reaction. Acetonitrile was added to the spin-dried reaction flask, and the mixture was poured into a column chromatography packed with C18 to decolorize and purify the mixture. When the excess DDQ is completely removed, CH₂Cl₂MeOH ═ 3:1 gave compound 18-c (68mg, 91.5%) as a final product. TOF-MS M/z 1703.4[ M-H ]]⁺. HPLC purity: 96.5 percent

Comparative example 1

Compound 17(50mg,0.022mmol) and Pd (400mg) were added to a hydrogenation kettle, dissolved in THF: h₂O4: 1(20mL), 1MPa,30 ℃ for 24 h. Quench with a drop of triethylamine and filter the reaction and spin dry. Purification by decolorizing in column chromatography using C18 packing afforded the final product, Compound 18(12mg, 32.4%). The TLC plate layer shows that the raw material is remained, the impurity points are more, and the raw material is not reduced for a prolonged time. The yield and purity are clearly inferior to the above examples.

As can be seen from the above, the allyl ligand used in the invention avoids the subsequent hydrogenation reaction, and the reaction can be completed under the condition of using the tetratriphenylphosphine for 1.5 h. The final product can be obtained after simple decolorization by using a C18 packed column. The problems of more impurities, lower yield and complex purification mode caused by hydrogenation debenzylation protecting group in the prior art are solved. Has obviously better effect.

(2) Compared with the prior art which needs hydrogenation reaction of palladium on carbon for more than 20h and then repeated filtration and ion column chromatography, the yield is lower (only can reach about 50%), the method using the Nap protecting group simplifies the operation, the yield of the deprotection step can reach more than 91.5% after optimization, and the purity reaches 97% (the determination method refers to that the content of MPL in the BLP25 liposome vaccine is determined by an HPLC-ELSD method, and Chinese medicines are listed as Juanxuan, Wang and Chang at No. 26 and No. 5 in 2012).

Claims

1. A preparation method of a compound shown as a formula 6 is characterized by comprising the following steps;

Carrying out imidization reaction shown as the following to obtain the compound shown as the formula 6; wherein n1 is 10, 12 or 14, n2 is 8, 10 or 12;

2. the process according to claim 1 for the preparation of a compound of formula 6,

the organic solvent is halogenated alkane solvent;

and/or the mass volume ratio of the compound shown as the formula 5 to the organic solvent is 10g/L-100 g/L;

and/or the alkali is organic alkali and/or inorganic alkali;

and/or the molar ratio of the alkali to the compound shown in the formula 5 is 1:1-3: 1;

and/or the presence of a gas in the gas,

the mol ratio of the compound to the compound shown in the formula 5 is 1:1-10: 1;

and/or the temperature of the imidization reaction is 0-50 ℃;

and/or the imidization reaction is carried out under the protection of inert gas;

and/or, the post-treatment of the imidization reaction comprises the following steps: after the imidization reaction is finished, concentrating, separating and purifying to obtain the product;

and/or n1 is 10, 12 or 14 and n2 is 10.

3. The process according to claim 2 for the preparation of a compound of formula 6,

the organic solvent is dichloromethane and/or trichloromethane;

and/or the mass volume ratio of the compound shown as the formula 5 to the organic solvent is 50g/L-80 g/L;

and/or the base is 1, 8-diazabicyclo [ 5.4.0%]Undec-7-ene, K₂CO₃DIPEA, NaH and Cs₂CO₃One or more of;

and/or the molar ratio of the alkali to the compound shown in the formula 5 is 1.8:1-2.2: 1;

and/or the presence of a gas in the gas,

the mol ratio of the compound to the compound shown in the formula 5 is 5:1-8: 1;

and/or the temperature of the imidization reaction is 10-30 ℃;

and/or, when the imidization reaction is carried out under the protection of inert gas, the inert gas can be nitrogen or argon;

and/or, when the post-treatment of the imidization reaction comprises the following steps: after the imidization reaction is finished, concentrating, separating and purifying, namely, when the imidization reaction is finished, the separation and purification is column chromatography separation, and the eluent for the column chromatography separation is alkalized petroleumA mixed solution of ether and ethyl acetate; for example, petroleum ether/ethyl acetate in a volume ratio of 15:1, containing 0.1% by volume Et₃N；

And/or n1 is 10 or 12 and n2 is 10.

4. The method for preparing a compound represented by the formula 6 according to any one of claims 1 to 3, further comprising the steps of; in an organic solvent, in the presence of a TBS removing protective agent, carrying out TBS removing protective group reaction on a compound shown as a formula 4 to obtain a compound shown as a formula 5; n1 and n2 are both as defined in any one of claims 1 to 3;

5. the process according to claim 4 for the preparation of the compound of formula 6,

in the TBS protecting group removing reaction, the organic solvent is a cyclic ether solvent;

and/or the mass volume ratio of the compound shown as the formula 4 to the organic solvent is 5g/L-100 g/L;

and/or, the TBS removing protective agent is a hydrofluoric acid pyridine complex;

and/or the volume-mass ratio of the TBS removal protective agent to the compound shown in the formula 4 is 1mL/g-20 mL/g;

and/or the temperature of the TBS deprotection reaction is-80 ℃ to 50 ℃;

and/or, the TBS protecting group removing reaction adopts the following steps: adding the TBS removing protective agent into the mixed system of the compound shown in the formula 4 and the solvent to carry out the TBS removing protective group reaction; the adding temperature is-70 ℃ to-30 ℃; after the addition is finished, the temperature of the TBS protecting group removing reaction is 0-30 ℃;

and/or, after said TBS deprotection reactionThe treatment comprises the following steps: after the TBS protecting group removing reaction is finished, quenching, extracting by using an organic solvent, drying, filtering, concentrating, separating and purifying to obtain the TBS protecting group removing product; the quenching can adopt saturated sodium bicarbonate solution; the extracted organic solvent can be halogenated alkane solvent; such as CH₂Cl₂(ii) a The separation and purification is preferably column chromatography separation, and the eluent for the column chromatography separation can be petroleum ether and ethyl acetate; for example, the volume ratio of petroleum ether to ethyl acetate is 4: 1.

6. The process according to claim 5 for the preparation of the compound of formula 6,

in the TBS protecting group removing reaction, the organic solvent is tetrahydrofuran;

and/or the mass volume ratio of the compound shown as the formula 4 to the organic solvent is 10g/L-50 g/L;

and/or, when the TBS removing protective agent is a pyridine hydrofluoric acid complex, the pyridine hydrofluoric acid complex is a pyridine solution;

and/or the volume-mass ratio of the TBS removal protective agent to the compound shown in the formula 4 is 3mL/g-10 mL/g;

and/or the temperature of the TBS deprotection reaction is-40 ℃ to 30 ℃;

and/or, the TBS protecting group removing reaction adopts the following steps: adding the TBS removing protective agent into the mixed system of the compound shown in the formula 4 and the solvent to carry out the TBS removing protective group reaction; the adding temperature is-40 ℃; after the addition is finished, the temperature of the TBS protecting group removing reaction is 0-30 ℃;

and/or, when the post-treatment of the TBS deprotection reaction comprises the following steps: after the TBS protecting group removing reaction is finished, quenching, extracting by using an organic solvent, drying, filtering, concentrating, separating and purifying, wherein when the TBS protecting group removing reaction is finished, saturated sodium bicarbonate solution is adopted for quenching; the extracted organic solvent is halogenated alkane solvent; the separation and purification is column chromatography separation, and the eluent for the column chromatography separation is petroleum ether and ethyl acetate.

7. The method of claim 4, further comprising the steps of:

step (1), carrying out phosphorylation reaction on a compound shown as a formula 3 and an allyl ligand in an organic solvent in the presence of tetrazole to obtain a mixture 1; the allyl ligand is hexadiene-N, N-diisopropyl phosphoramidite;

step (2), carrying out oxidation reaction on the mixture 1 and an oxidant to obtain the compound shown as the formula 3; n1 and n2 are both as defined in claim 4;

further, it may comprise the step of reacting borane, a Lewis acid and H in an organic solvent₂In the presence of O, carrying out a selective reduction ring-opening reaction on the compound shown as the formula 2 as shown in the specification to obtain the compound shown as the formula 3; n1 and n2 are both as defined above;

still further, it may further comprise the steps of: in an organic solvent, in the presence of a condensing agent and a catalyst, carrying out an esterification reaction shown in the specification on a compound shown in a formula 1 and a compound shown in a formula 19B to obtain a compound shown in a formula 2; n1 and n2 are both as defined in claim 7;

8. a compound shown as a formula 6 and a formula 5;

wherein n1 and n2 are each as defined in any one of claims 1 to 3.

9. A compound of formula 6 or 5 according to claim 8, wherein;

wherein, the compound shown in the formula 6 is any one of the following compounds:

wherein, the compound shown in the formula 5 is any one of the following compounds:

10. a preparation method of a compound shown as a formula 5 is characterized by comprising the following steps:

in an organic solvent, in the presence of a TBS removing protective agent, carrying out TBS removing protective group reaction on a compound shown as a formula 4 to obtain a compound shown as a formula 5; n1 and n2 are both as defined in claim 8 or 9;

the reaction conditions and operations in the process for preparing the compound represented by the formula 5 are as described in any one of claims 4 to 7.